Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.56 |
| ▸ | PDE4A | P27815 | 14/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120049 | 0.99 | ADORA2A (0.54) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3990425 | 0.80 | PDE4A (0.57) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10420653 | 0.78 | PDE4A (0.49) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6251096 | 0.76 | PDE4A (0.64) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21381252 | 0.75 | ADORA2A (0.82) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28973355 | 0.75 | LMNA (0.62) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7162120 | 0.72 | ADORA2A (0.47) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21381260 | 0.71 | ADORA2A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3171115 | 0.71 | ADORA2A (0.55) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL316171 | 0.71 | PDE4A (0.82) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023170099-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-09-14 | — | — | WO | disclosed |
| CN-108329372-A | N6(2- ethoxys）Adenosine and its derivative are preparing the application in treating gout drug | 柴秋 | 2018-07-27 | — | — | CN | disclosed |
| CN-106405067-B | A kind of detection method of the drug target residence time based on full cell | 徐州医科大学 | 2018-03-30 | — | — | CN | disclosed |
| CN-106405067-A | Whole cell-based detection method of residence time of medicinal target point | 徐州医科大学 | 2017-02-15 | — | — | CN | disclosed |
| CN-1257160-C | Aminoquinoline derivatives and their use as adenosine A3 ligands | PASTEUR SANOFI DIAGNOSTICS (FR) | 2006-05-24 | — | — | CN | disclosed |
| CN-1512985-A | Aminoquinoline and aminopiperidine derivatives and their use as adenosine A3 ligands | ��ŵ�Ѻϳ�ʵ���� | 2004-07-14 | — | — | CN | disclosed |
| EP-0686155-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-13 | — | — | EP | disclosed |
| WO-1994019349-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |